Novo Nordisk (NVO)
(Real Time Quote from BATS)
$142.61 USD
+3.74 (2.69%)
Updated Jul 5, 2024 03:55 PM ET
After-Market: $142.42 -0.19 (-0.13%) 4:14 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
NVO 142.61 +3.74(2.69%)
Will NVO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NVO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVO
J&J (JNJ) Trades Below 200 & 50-Day Moving Averages: Buy the Dip?
NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss
NVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viking (VKTX) Skyrockets 197% YTD: Is the Stock Worth a Buy?
Take the Zacks Approach to Beat the Markets: NVIDIA, Seagate, Amkor in Focus
HIMS Stock Tumbles: Here's Why It's a Buy Right Now
Other News for NVO
Study links Novo Nordisk jabs to condition that can cause blindness
Stock market today: Asian shares mostly rise, boosted by Wall Street records as Tesla zooms
Novo Nordisk price target raised by DKK 305 at UBS
The Top 3 Weight Loss Drug Stocks to Buy for Huge Gains
UBS Sticks to Its Hold Rating for Novo Nordisk (0QIU)